WO2001093844A3 - Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist - Google Patents
Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist Download PDFInfo
- Publication number
- WO2001093844A3 WO2001093844A3 PCT/US2001/010824 US0110824W WO0193844A3 WO 2001093844 A3 WO2001093844 A3 WO 2001093844A3 US 0110824 W US0110824 W US 0110824W WO 0193844 A3 WO0193844 A3 WO 0193844A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- serotonin transporter
- transporter inhibitor
- ht1d antagonist
- ht1d
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001262928A AU2001262928A1 (en) | 2000-06-02 | 2001-05-21 | Pharmaceutical compositions and their use |
US10/276,107 US20030212109A1 (en) | 2000-06-02 | 2001-05-21 | Pharmaceutical compositions and their use |
EP01937165A EP1299120A2 (en) | 2000-06-02 | 2001-05-21 | Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0013503.8 | 2000-06-02 | ||
GB0013503A GB2362826A (en) | 2000-06-02 | 2000-06-02 | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001093844A2 WO2001093844A2 (en) | 2001-12-13 |
WO2001093844A3 true WO2001093844A3 (en) | 2002-04-04 |
Family
ID=9892909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010824 WO2001093844A2 (en) | 2000-06-02 | 2001-05-21 | Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1299120A2 (en) |
AU (1) | AU2001262928A1 (en) |
GB (1) | GB2362826A (en) |
WO (1) | WO2001093844A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533267A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
EP0701819A2 (en) * | 1994-09-14 | 1996-03-20 | Pfizer Inc. | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
EP0780388A1 (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Limited | 5HT1Dalpha and 5HT2A ligands |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
PA8469101A1 (en) * | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | AZABICICLIC LEAGUES OF RECEIVERS 5HT1 |
WO1999059593A1 (en) * | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
-
2000
- 2000-06-02 GB GB0013503A patent/GB2362826A/en not_active Withdrawn
-
2001
- 2001-05-21 WO PCT/US2001/010824 patent/WO2001093844A2/en not_active Application Discontinuation
- 2001-05-21 AU AU2001262928A patent/AU2001262928A1/en not_active Abandoned
- 2001-05-21 EP EP01937165A patent/EP1299120A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533267A1 (en) * | 1991-09-18 | 1993-03-24 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
EP0701819A2 (en) * | 1994-09-14 | 1996-03-20 | Pfizer Inc. | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
EP0780388A1 (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Limited | 5HT1Dalpha and 5HT2A ligands |
Also Published As
Publication number | Publication date |
---|---|
WO2001093844A2 (en) | 2001-12-13 |
GB2362826A (en) | 2001-12-05 |
AU2001262928A1 (en) | 2001-12-17 |
EP1299120A2 (en) | 2003-04-09 |
GB0013503D0 (en) | 2000-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001035941A3 (en) | Novel composition based on a thiazolidinedione and metformin and use | |
AP2003002916A0 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. | |
AU2002236883A1 (en) | Microplate storage, transport, and conveyor system | |
AU2003289440A1 (en) | Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof | |
EP1587474A3 (en) | Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses | |
IL168784A (en) | Fused 1,3-dihydroimidazole ring compounds and pharmaceutical compositions comprising the same | |
AU2002239282A1 (en) | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof | |
IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
AU2001289751A1 (en) | Selective pde 2 inhibitors, used as medicaments for improving cognition | |
HK1048271A1 (en) | Pharmaceutical composition for inhibiting retinoidskin damage. | |
MXPA03005257A (en) | Nmda receptor agonist pharmaceutical compositions. | |
HUP0101333A3 (en) | Diazepan derivatives and their salts, pharmaceutical compositions containing the same | |
HUP0401638A3 (en) | Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same | |
MXPA03003314A (en) | C-nitrosoaniline compounds and their blends as polymerization inhibitors. | |
WO2006072070A3 (en) | Pharmaceutical formulations of gallium salts | |
AU2001282088A1 (en) | Immunosuppressive, antiinflammatory and analgetic compounds | |
HK1050610A1 (en) | Microemulsion aerosol composition. | |
AP2004003066A0 (en) | Pharmaceutical compositions based on azetidine derivatives. | |
AU2002211176A1 (en) | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 | |
AU2001292331A2 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
WO2001093844A3 (en) | Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist | |
NZ516634A (en) | Rest-breaking composition for use with deciduous fruit species | |
MXPA03001557A (en) | Biphenyl derivatives and the use thereof as integrin inhibitors. | |
AU2003296168A1 (en) | Chuck device of container, transportation device with the same, and chuck claw for the transportation device | |
HK1050896A1 (en) | Amino acid derivatives and use thereof as nep, aceand ece inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10276107 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001937165 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001937165 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001937165 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |